Railway Pension Investments Ltd Sells 7,769 Shares of Gilead Sciences, Inc. $GILD

Railway Pension Investments Ltd trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,295,596 shares of the biopharmaceutical company’s stock after selling 7,769 shares during the period. Gilead Sciences comprises 2.1% of Railway Pension Investments Ltd’s portfolio, making the stock its 19th biggest holding. Railway Pension Investments Ltd owned about 0.10% of Gilead Sciences worth $163,686,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Persistent Asset Partners Ltd bought a new position in Gilead Sciences in the 2nd quarter worth $25,000. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the fourth quarter valued at about $25,000. Kimelman & Baird LLC bought a new position in shares of Gilead Sciences in the second quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the period. Finally, Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $26,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on GILD. Barclays dropped their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Rothschild & Co Redburn lowered their target price on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. HSBC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Finally, Morgan Stanley reduced their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a report on Monday, July 27th. Twenty-four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Trading Up 0.5%

Shares of Gilead Sciences stock opened at $146.34 on Tuesday. The stock has a market cap of $181.46 billion, a PE ratio of -54.81 and a beta of 0.32. The firm has a fifty day moving average price of $134.68 and a 200 day moving average price of $136.50. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the firm earned $2.01 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.5 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the sale, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the sale, the insider directly owned 118,234 shares in the company, valued at $16,273,727.76. The trade was a 19.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 90,000 shares of company stock valued at $12,266,220 over the last 90 days. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.